Combined therapy using HIF-1α gene delivery and MSCs in a myocardial infarction model enhanced angiogenesis and cardiac function compared to monotherapies, possibly due to improved MSC engraftment [159]. This evidence concerns the gene HIF1A and myocardial infarction.